The emerging therapy of islet transplantation has shown great promise for diabetes patients.
CONTEXT: The emerging therapy of islet transplantation has shown great promise for diabetes patients. When grafted in the liver, pancreatic islet cells, which restore normoglycemia, have helped individuals with type 1 diabetes become insulin-independent. Doctors at the Martinos Center for Biological Imaging at Massachusetts General Hospital are investigating a method for tracking the fate of these islets in vivo with MRI. In initial animal studies, Dr. Anna Moore and colleagues used in-house synthesized magnetic iron oxide nanoparticles that detect transplanted pancreatic islets in vivo but do not hinder the cells' ability to produce insulin. To introduce this imaging method in a clinical setting, Moore's team tested the technique using Feridex, a widely available FDA-approved iron oxide-based contrast agent.
RESULTS: Human pancreatic islet cells tagged with iron oxide nanoparticles and transplanted under the kidney capsule in mice retained their ability to secrete insulin and restore normoglycemia in diabetic animals. They were readily detectable by in vivo MRI up to 188 days after transplantation (Evgenov N et al. In vivo imaging of islet transplantation. Nat Med 2006;12:144-148). In a more relevant clinical scenario, pancreatic islet cells were labeled with Feridex and transplanted through the portal vein into the liver. They appeared as dark voids on T2-weighted gradient-echo pulse sequences, whereas nonlabeled islets were not detectable by MRI.
IMAGE: In vivo imaging of human pancreatic islet cells labeled with Feridex in clinically relevant model of intrahepatic transplantation in mice (A). Nonlabeled islets are not detectable by MRI (B). (Provided by A. Moore)
IMPLICATIONS: Results indicate MRI can follow the fate of islet cells labeled with Feridex in a mouse model. The protocol will be applied to baboons at the Martinos Center before clinical trials involving humans. The next step is to find a means of detecting islet function noninvasively to measure the insulin that is secreted by these cells, Moore said.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study Says Contrast-Enhanced Mammography Offers Comparable Breast Cancer Detection to MRI
November 15th 2023In findings from an enriched cohort of asymptomatic patients with screening-detected abnormalities, researchers found that contrast-enhanced mammography (CEM) was superior to conventional mammography and offered equivalent detection of breast cancer in comparison to breast MRI and abbreviated breast MRI.
Adjunctive Brain Volume Quantification Tool for MRI Gets FDA Clearance
November 14th 2023Providing automated brain volume calculations based on MRI images, NeuroShield’s artificial intelligence (AI)-powered technology may help facilitate treatment for neurodegenerative conditions ranging from Alzheimer’s disease to epilepsy.